Nature Biotechnology - CURRENT ISSUE : July 2008 - Vol 26 No 7
- Blood and guts: an oral angiogenesis inhibitor
- Fingers point way to HIV-resistant T cells
- Small molecule targets arthritis
LATEST HIGHLIGHTS
ADVANCE ONLINE PUBLICATION
Safer antibody-drug conjugates
Article by Junutula et al.Antibody-drug conjugates (ADCs) for cancer therapy are limited by toxicity associated with heterogeneity in the stoichiometries and sites of drug attachment. Junutula et al. produce near-homogenous ADCs that are better tolerated than conventional ADCs without any loss of antitumor activity.
ADVANCE ONLINE PUBLICATION
Homogeneous reprogrammable mouse tissues
Article by Wernig et al.Generating induced pluripotent stem (iPS) cells is still an inefficient process, in part because the delivery of reprogramming factors by retroviral vectors yields cell populations that are genetically heterogeneous. Wernig et al. increase efficiency by producing iPS-cell chimeric mice from which they isolate cells bearing identical proviral insertions that support drug-inducible reprogramming.
Focus Issue
The global impact of viral infection, the development of resistance to current drugs and the continuing threat of global pandemics due to the emergence of new viruses translate into unique scientific and strategic challenges. Together with Nature Reviews Drug Discovery, Nature Biotechnology has put together a joint web focus that tackles these issues. We are grateful to our principal sponsor Pfizer and supporting sponsor Gilead Sciences for assistance.
NEW!
SciBX can save you time and resources by identifying and describing key translational research, identifying novel competition, and facilitating early opportunities for investment, alliances and partnerships. SciBX provides both scientific and commercial perspectives on the most important 25 scientific papers each week.
Subscribe today at www.scibx.com
ADVANCE ONLINE PUBLICATION
Small molecule enhances RNAi activity
Article by Shan et al.Little is known about the regulation of RNA interference (RNAi). Shan et al. construct a reporter system to monitor RNAi activity and identify a small molecule that increases RNAi by facilitating the interaction between small RNAs and a protein involved in small RNA loading and processing.
CURRENT ISSUE
HIV-proof T cells
Article by Perez et al.The HIV co-receptor CCR5 is a promising target for anti-HIV therapies. Perez et al. use an engineered zinc-finger nuclease to specifically knock out CCR5 in primary human T cells. The modified T cells are resistant to CCR5-tropic HIV in mice, leading to lower viral loads and higher T-cell counts.
Impact Factor
The 2006 impact factor for Nature Biotechnology is 22.7, according to the ISI Journal Citation Reports. This places Nature Biotechnology first among primary research journals in the field of biotechnology.
Web Portal
Getting sued over intellectual property costs time and money. There are ways to reduce the risk of it happening to you.
